ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 53 filers reported holding ALIGOS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,551,071 | -23.1% | 2,076,400 | 0.0% | 0.01% | -25.0% |
| Q2 2023 | $2,016,184 | +11.1% | 2,076,400 | 0.0% | 0.01% | +20.0% |
| Q1 2023 | $1,814,774 | -8.3% | 2,076,400 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $1,978,602 | -13.4% | 2,076,400 | 0.0% | 0.01% | -20.0% |
| Q3 2022 | $2,284,000 | -9.1% | 2,076,400 | 0.0% | 0.02% | +7.1% |
| Q2 2022 | $2,512,000 | -43.7% | 2,076,400 | 0.0% | 0.01% | -46.2% |
| Q1 2022 | $4,464,000 | -81.9% | 2,076,400 | 0.0% | 0.03% | -78.3% |
| Q4 2021 | $24,647,000 | -23.5% | 2,076,400 | 0.0% | 0.12% | -14.9% |
| Q3 2021 | $32,205,000 | -1.9% | 2,076,400 | +29.0% | 0.14% | -2.1% |
| Q2 2021 | $32,820,000 | -10.4% | 1,610,000 | 0.0% | 0.14% | -9.4% |
| Q1 2021 | $36,611,000 | -17.8% | 1,610,000 | 0.0% | 0.16% | -5.4% |
| Q4 2020 | $44,517,000 | – | 1,610,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |